Summit Therapeutics Inc. Common Stock
Summit Therapeutics Inc. Common Stock price
About Summit Therapeutics Inc. Common Stock
Summit Therapeutics Inc. is a biopharmaceutical firm dedicated to discovering, developing, and commercializing therapeutic solutions, primarily targeting infectious diseases across the United States and Latin America. The company's clinical development pipeline is heavily concentrated on therapies for Clostridioides difficile infection (CDI). Its flagship product candidate, ridinilazole, is an orally administered small molecule antibiotic currently advancing through Phase III clinical trials as a treatment for CDI. Beyond its lead asset, Summit Therapeutics is also progressing SMT-738, designed to combat multidrug-resistant infections, notably carbapenem-resistant Enterobacteriaceae (CRE). Additionally, its DDS-04 series represents a potential therapeutic avenue for various infections caused by the Enterobacteriaceae family of bacteria. Established in 2003, the company maintains its headquarters in Cambridge, Massachusetts.
- Stock ticker
- SMMT
- Company
- Summit Therapeutics Inc.
- Industry
- Healthcare
- Category
- US
- Stock split / reverse split
- --
- Launch date
- Mar 5, 2015
- Listed exchange
- NASDAQ
Financials
Summary: EPS of -0.28 (+63.16%), missing expectations.
Summit Therapeutics Inc. Common Stock conversion tables
 |  |
|---|---|
| 0.5 SMMT | 7.910 USD |
| 1 SMMT | 15.82 USD |
| 5 SMMT | 79.1 USD |
| 10 SMMT | 158.2 USD |
| |
|---|---|
| 0.5 USD | 0.031606 SMMT |
| 1 USD | 0.063211 SMMT |
| 5 USD | 0.31606 SMMT |
| 10 USD | 0.63211 SMMT |
More to explore
FAQ
SMMT is trading at $15.82, -1.68% over the last 24 hours. Track live moves on the price chart at the top of this page.
The SMMT stock forecast depends on a mix of factors — broader market conditions, sector trends, and company-specific drivers like earnings, product cycles, and macro signals. SMMT is currently trading at $15.82, -1.68% over the last 24 hours, which reflects how the market is pricing these factors today. For a longer-term outlook on SMMT price action, review the 30-day, 60-day, and 90-day performance shown above, monitor momentum across the Healthcare sector, and watch overall market sentiment. Stock forecasts and price predictions are inherently uncertain — always DYOR.
P/E ratio (Price-to-Earnings, trailing twelve months) measures how much investors pay per dollar of earnings over the last 12 months. SMMT's P/E ratio is currently -- — calculated by dividing its share price by its trailing 12-month earnings per share (EPS). A higher P/E suggests investors expect stronger future growth from SMMT; a lower P/E may indicate the stock is undervalued or that the market is pricing in a weaker outlook. P/E ratios are most useful when compared against SMMT's historical range and other companies in the Healthcare sector.
Summit Therapeutics Inc.'s market cap is currently 12.83B USD. Market cap is calculated as stock price × total shares outstanding.
Disclaimer
The social content on this page ("Content"), including but not limited to tweets and statistics provided by LunarCrush, is sourced from third parties and provided "as is" for informational purposes only. OKX does not guarantee the quality or accuracy of the Content, and the Content does not represent the views of OKX. It is not intended to provide (i) investment advice or recommendation; (ii) an offer or solicitation to buy, sell or hold digital assets; or (iii) financial, accounting, legal or tax advice. Digital assets, including stablecoins and NFTs, involve a high degree of risk and can fluctuate greatly. The price and performance of the digital assets are not guaranteed and may change without notice.
OKX does not provide investment or asset recommendations. You should carefully consider whether trading or holding digital assets is suitable for you in light of your financial condition. Please consult your legal/tax/investment professional for questions about your specific circumstances. For further details, please refer to our Terms of Use and Risk Warning.